Statistics

Total Visits

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer45

Select a period of time:

Number of views in the range

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer12

Views

Views
October 20250
November 20253
December 20250
January 20262
February 20260
March 20262
April 20265
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
Brazil2
Finland2
United Kingdom2
 

Top cities views

Views
Helsinki2
Boston1
Canaã dos Carajás1
Franca1
Manchester1
New York1
Utica1